All In Biotech

Drug Trial Radar · NCT04729114

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Phase 1, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

174

Planned (sponsor's estimate)

Start

Jun 14, 2021

Primary completion

May 31, 2029

Study completion May 31, 2029

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Jan 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their cancer has come back after previous cancer treatment, or the previous cancer treatment they had didn't work. The main aims of the study are: * to check the safety of PRL-02 depot given with and without another medicine called enzalutamide. * to check if the men can tolerate PRL-02 depot given with or without enzalutamide. * to find a suitable dose of PRL-02 depot. This study will be in 2 parts. In the first part, different small groups of men will receive lower to higher doses of PRL-02 depot together with other medicines. In the second part of the study, men who have previously taken a hormone therapy called abiraterone acetate or have previously taken 1 specific hormone therapy as part of their prostate cancer treatment can take part. Men in both parts of the study will receive injections of PRL-02 depot into a muscle once every 12 weeks. They will also take dexamethasone or prednisone, or enzalutamide once a day. The other medicines they take depend on which group and which part of the study they are in. During the study, the men will visit the clinic several times for health checks and scans. After the final visit, men whose cancer has not become worse will continue to have health checks and scans every few months.

Conditions

  • Prostate Cancer
  • Metastatic Castration Resistant Prostate Cancer
  • Metastatic Castration-sensitive Prostate Cancer

Interventions

  • PRL-02 injectionDrug

    abiraterone decanoate for intramuscular injection

  • prednisoneDrug

    Oral dose

  • dexamethasoneDrug

    Oral dose

  • enzalutamideDrug

    Oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days
  2. Number of Participants with Adverse Events (AEs)Time frame: Up to 4 years
  3. Number of Participants with Serious Adverse Events (SAEs)Time frame: Up to 4 years
  4. Number of Participants with laboratory value abnormalities and/or AEsTime frame: Up to 4 years
  5. Number of Participants with electrocardiogram (ECG) abnormalities and/or AEsTime frame: Up to 4 years
  6. Number of Participants with vital sign abnormalities and/or AEsTime frame: Up to 4 years
  7. Number of Participants with physical exam abnormalities and/or AEsTime frame: Up to 4 years
  8. Number of Participants with Eastern Cooperative Oncology Group (ECOG) performance status scoreTime frame: Up to 4 years
  9. Testosterone Suppression of Participants as Assessed by Testosterone LevelsTime frame: Up to 4 years

Locations

25 sites in 2 countries. Site status is shown where the registry gives one.

  • Arizona Urology Specialists

    Tucson, Arizona · Withdrawn

  • Los Angeles Cancer Network

    Anaheim, California · Recruiting

  • Providence Medical Group Oncology Santa Rosa

    Santa Rosa, California · Recruiting

  • Florida Urology Partners

    Tampa, Florida · Withdrawn

  • Fort Wayne Medical Oncology and Hematology, Inc.

    Fort Wayne, Indiana · Withdrawn

  • First Urology

    Jeffersonville, Indiana · Recruiting

  • Wichita Urology Group

    Wichita, Kansas · Recruiting

  • National Cancer Institute

    Bethesda, Maryland · Withdrawn

  • Chesapeake Urology

    Towson, Maryland · Recruiting

  • XCancer Center Omaha/Urology Cancer Center

    Omaha, Nebraska · Completed

  • Garden Sate Urology

    Morristown, New Jersey · Withdrawn

  • New Mexico Oncology Hematology Consultants Ltd

    Albuquerque, New Mexico · Recruiting

  • Duke Cancer Center

    Durham, North Carolina · Recruiting

  • Helios Clinical Research, LLC

    Middleburg Heights, Ohio · Withdrawn

  • Toledo Clinical Cancer Center

    Toledo, Ohio · Withdrawn

  • MidLantic Urology

    Bala-Cynwyd, Pennsylvania · Recruiting

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina · Recruiting

  • Urology Associates PC

    Nashville, Tennessee · Recruiting

  • Urology Clinics of North Texas

    Dallas, Texas · Recruiting

  • Houston Metro Urology

    Houston, Texas · Recruiting

  • Oncology Consultants

    Houston, Texas · Withdrawn

  • Urology San Antonio

    San Antonio, Texas · Withdrawn

  • University of Virginia Cancer Center

    Charlottesville, Virginia · Recruiting

  • Northwest Medical Specialties

    Tacoma, Washington · Recruiting

  • Pan American Center for Oncology Trials, LLC

    San Juan, Rio Piedras, Puerto Rico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.